Golden Gift

Jingift Biopharma is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on the discovery and development of innovative therapies for metabolic and digestive diseases. The company targets high-prevalence conditions with significant unmet medical needs, such as non-alcoholic steatohepatitis (NASH/MASH), obesity, and type 2 diabetes. Jingift utilizes a proprietary drug discovery platform that combines structure-based drug design with advanced protein engineering to develop both small molecule and biologic candidates. Its lead program, JGT-021, is a long-acting FGF21 fusion protein currently undergoing Phase 2 clinical evaluation for NASH. Additionally, the company is advancing JGT-031, an oral small molecule GLP-1 receptor agonist, through early-stage clinical trials. Jingift is backed by leading venture capital firms including Matrix Partners China and Qiming Venture Partners.